Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cdc1-dependent antitumor immunity in hnscc

HIGHLIGHTS

• who: Robert Saddawi-Konefka from the Diego School University of, Robert W Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR, USA have published the article: Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC, in the Journal: NATURE COMMUNICATIONS NATURE COMMUNICATIONS
• what: The authors explore this hypothesis using syngeneic animal models of HNSCC to develop a rational approach for the effective use of IO therapies in HNSCC. The authors focused on conventional type I dendritic cells (cDC1s), which are recognized as the most potent cross-presenting immune . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.